{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-009382","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.602470+00:00","generated_at":"2026-06-17T11:18:57.717861+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Abeona Therapeutics FY2022 net loss narrows to $43.5M; EB-101 BLA submission on track","bullets":["Net loss $43.5M ($5.53/share) vs $84.9M ($21.57/share) in FY2021 as expense reductions offset lower revenue.","Cash of $52.5M at Dec 31, 2022 ($50.9M at Dec 31, 2021); expected to fund operations into Q3 2024.","Plans to submit BLA for EB-101 (RDEB) to FDA in late Q2/early Q3 2023, based on positive Phase 3 VIITAL results.","Appointed Dmitriy Grachev as CMO; Madhav Vasanthavada as VP Business Development; Amanda Moore promoted to VP.","Completed $35M private placement in November 2022 with institutional investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-009382","json":"https://secwatch.observer/filing/0001493152-23-009382.json","markdown":"https://secwatch.observer/filing/0001493152-23-009382.md","text":"https://secwatch.observer/filing/0001493152-23-009382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T11:18:57.717861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fbd77a66548c6a1bb70754b3ef5218811ae51d6d","claim":"ABEONA THERAPEUTICS INC. reported full year 2022 results: revenue $1.4 million, net income $5.53 loss per common share.","evidence_excerpt":"License and other revenues for the year ended December 31, 2022 were $1.4 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Revenue","value":"$1.4 million"},{"label":"Net income","value":"$5.53 loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}